for the treatment of adult patients with certain types of metastatic bladder or urinary tract cancer. Following a consultation with the US Food and Drug Administration (FDA), and in accordance ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...